Rivoceranib-Camrelizumab
Elevar Therapeutics Announces FDA Acceptance of Rivoceranib-Camrelizumab Combo for Liver Cancer
SG Tylor
On July 17, 2023 Elevar Therapeutics, a fully integrated biopharmaceutical company focused on improving treatment options for patients with limited ...